Candel Therapeutics Inc
CADL5.830USD
+0.540+10.21%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
320.04MMarket Cap
LossP/E TTM
More Details of Candel Therapeutics Inc Company
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Candel Therapeutics Inc Info
Ticker SymbolCADL
Company nameCandel Therapeutics Inc
IPO dateJul 27, 2021
CEOTak (Paul Peter)
Number of employees38
Security typeOrdinary Share
Fiscal year-endJul 27
Address117 Kendrick Street,
CityNEEDHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02494
Phone16179165445
Websitehttps://www.candeltx.com/
Ticker SymbolCADL
IPO dateJul 27, 2021
CEOTak (Paul Peter)
Company Executives of Candel Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+42826.00%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4282.00%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+5353.00%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Renee M. Gaeta, CPA
Ms. Renee M. Gaeta, CPA
Independent Director
Independent Director
--
--
Dr. Gary J. Nabel, M.D., Ph.D.
Dr. Gary J. Nabel, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+42826.00%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4282.00%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+5353.00%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Revenue Breakdown
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
Manning (Paul B.)
5.14%
Acorn Capital Advisors, LLC
4.70%
Aguilar-Cordova (Estuardo)
4.41%
Aguilar (Laura K)
4.29%
Other
66.46%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
Manning (Paul B.)
5.14%
Acorn Capital Advisors, LLC
4.70%
Aguilar-Cordova (Estuardo)
4.41%
Aguilar (Laura K)
4.29%
Other
66.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.14%
Individual Investor
15.75%
Investment Advisor/Hedge Fund
8.05%
Corporation
2.37%
Hedge Fund
1.84%
Research Firm
0.31%
Bank and Trust
0.12%
Pension Fund
0.11%
Insurance Company
0.03%
Other
39.27%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
162
22.92M
49.81%
+771.00
2025Q3
163
22.99M
50.01%
-379.95K
2025Q2
155
23.37M
48.18%
+1.99M
2025Q1
149
21.38M
48.85%
-1.70M
2024Q4
121
18.49M
19.46%
+11.29M
2024Q3
102
7.20M
24.25%
+733.84K
2024Q2
85
6.85M
21.09%
+2.44M
2024Q1
54
4.66M
22.51%
-1.95M
2023Q4
53
4.83M
23.41%
-1.22M
2023Q3
56
6.00M
23.34%
-100.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
8.23M
15%
-50.00
-0.00%
Sep 30, 2025
Manning (Paul B.)
2.82M
5.14%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.7%
--
--
Sep 30, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.41%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.29%
-690.05K
-22.65%
Apr 21, 2025
The Vanguard Group, Inc.
2.01M
3.66%
+219.56K
+12.28%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.16M
3.94%
+77.88K
+3.73%
Sep 30, 2025
Portolan Capital Management, L.L.C.
1.38M
2.52%
-237.59K
-14.65%
Sep 30, 2025
BKB Growth Investments LLC
1.30M
2.37%
+750.00K
+135.44%
Apr 21, 2025
Geode Capital Management, L.L.C.
928.20K
1.69%
+24.23K
+2.68%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
0.12%
iShares Micro-Cap ETF
0.04%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Vanguard US Momentum Factor ETF
0%
iShares Russell 2000 Value ETF
0%
View more
ALPS Medical Breakthroughs ETF
Proportion0.12%
iShares Micro-Cap ETF
Proportion0.04%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Vanguard US Momentum Factor ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
